Design a Hybrid Organic–Pharmaceutical Matrix System for Controlled Drug Delivery: Case Study of Linking Tuneable Diclofenac Sodium Release via Hydrogenated Cottonseed Oil

The convergence of chemistry and applied pharmaceutical materials science enables the rational design of hybrid systems for sustained drug delivery. Hydrogenated cottonseed oil (HCSO), a lipid modified via organic hydrogenation, was investigated as a hydrophobic matrix-forming material within engineered pharmaceutical composites. Diclofenac sodium, a widely used nonsteroidal anti-inflammatory drug (NSAID), served as a model compound to explore the relationship between composition, matrix architecture, and drug release behaviour. Matrix tablets containing 30 mg diclofenac sodium were prepared by direct compression using varying ratios of HCSO, calcium sulphate, and lactose as a control matrix, generating hybrid organic–inorganic systems with tunable physicochemical properties. In vitro dissolution studies were performed using USP Apparatus II in 900 mL distilled water at 37 ± 0.5°C and 75 rpm over 24 hours, with drug release quantified by UV–Vis spectrophotometry at 276 nm.
Results demonstrate that HCSO acts as a hydrophobic phase, forming a diffusion-controlled barrier that modulates solvent penetration and drug mobility. Increasing HCSO content significantly retarded drug release: formulation D15H60Ca24 achieved ~81.05% release over 13 hours, while D15H24Ca60 showed slower kinetics (~48.89% over 24 hours), indicating enhanced matrix cohesion and reduced porosity. In contrast, lactose-based formulations promoted pore formation and rapid diffusion, enabling near-complete release within 5 hours. This study highlights how applied organic chemistry principles, including hydrophobicity, phase behaviour, and molecular interactions, can guide the design of pharmaceutical materials. HCSO-based systems represent sustainable, biodegradable platforms capable of precise modulation of drug release kinetics, supporting the development of scalable, cost-effective hybrid drug delivery systems.